Why is $BCRX moving today? · SEC 8-K archive

$BCRX SEC Filing Alert & Real-Time AI Stock Impact Analysis

T0 SEO archive for $BCRX: filings appear instantly. AI score, direction and bullet analysis unlock publicly after 4 hours (VIP sees them live).

← All archive signals

FAQ: $BCRX filing catalyst

Why did $BCRX trigger an AI stock catalyst alert?

$BCRX triggered a Stock Catalyst AI alert on 2026-11-04 00:00:00 UTC for a SEC 8-K filing (AI Score: +6.8/10). Headline: BioCryst Reports Q3 2026 Net Income of $37.9M, Raises Full-Year Revenue Guidance. Key points: - Total net revenue reached $180.3M with ORLADEYO generating $174.8M; operating profit was $53.3M. - Diluted EPS increased to $0.14 compared to $0.06 in the prior-year period. - Full-year 2026 total revenue guidance raised to $715M-$730M; Non-GAAP OpEx guidance improved to $415M-$425M.

How did $BCRX stock react after the SEC filing?

After the SEC 8-K for $BCRX, observed market reaction: T0 price $8.57. Past moves do not guarantee future results.

Where can I get real-time $BCRX SEC filing alerts?

Stock Catalyst AI pushes real-time SEC 8-K alerts for $BCRX via Telegram and the VIP Web Terminal from €10/month.

$BCRX – BioCryst Reports Q3 2026 Net Income of $37.9M, Raises Full-Year Revenue Guidance

BIOCRYST PHARMACEUTICALS INC
· SEC 8-K · All $BCRX

Unlocked archive · Analyzed in <2s at T0

Bullish AI Sentiment (+6.8 / 10)
  • Total net revenue reached $180.3M with ORLADEYO generating $174.8M; operating profit was $53.3M.
  • Diluted EPS increased to $0.14 compared to $0.06 in the prior-year period.
  • Full-year 2026 total revenue guidance raised to $715M-$730M; Non-GAAP OpEx guidance improved to $415M-$425M.